Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT
Por:
van Gorkom, G, van Gelder, M, Eikema, DJ, Blok, HJ, van Lint, MT, Koc, Y, Ciceri, F, Beelen, D, Chevallier, P, Selleslag, D, Blaise, D, Foa, R, Corradini, P, Castagna, L, Moreno, C, Solano, C, Muller, LP, Tischer, J, Hilgendorf, I, Hallek, M, Bittenbring, J, Theobald, M, Schetelig, J, Kroger, N, CLL Subcomm Chronic Malignancies
Publicada:
1 mar 2018
Resumen:
Allogeneic hematopoietic stem cell transplantation (HCT) may result in long-term disease control in high-risk chronic lymphocytic leukemia (CLL). Recently, haploidentical HCT is gaining interest because of better outcomes with post-transplantation cyclophosphamide (PTCY). We analyzed patients with CLL who received an allogeneic HCT with a haploidentical donor and whose data were available in the EBMT registry. In total 117 patients (74% males) were included; 38% received PTCY as GVHD prophylaxis. For the whole study cohort OS at 2 and 5 yrs was 48 and 38%, respectively. PFS at 2 and 5 yrs was 38 and 31%, respectively. Cumulative incidence (CI) of NRM in the whole group at 2 and 5 years were 40 and 44%, respectively. CI of relapse at 2 and 5 yrs were 22 and 26%, respectively. All outcomes were not statistically different in patients who received PTCY compared to other types of GVHD prophylaxis. In conclusion, results of haploidentical HCT in CLL seem almost identical to those with HLA-matched donors. Thereby, haploidentical HCT is an appropriate alternative in high risk CLL patients with a transplant indication but no available HLA-matched donor. Despite the use of PTCY, the CI of relapse seems not higher than observed after HLA-matched HCT.
Filiaciones:
van Gorkom, G:
Univ Med Ctr Maastricht, Maastricht, Netherlands
van Gelder, M:
Univ Med Ctr Maastricht, Maastricht, Netherlands
Eikema, DJ:
Leiden Univ, Dept Med Stat & Bioinformat, Med Ctr, Leiden, Netherlands
Blok, HJ:
Leiden Univ, Dept Med Stat & Bioinformat, Med Ctr, Leiden, Netherlands
van Lint, MT:
Osped San Martino Genova, Genoa, Italy
Koc, Y:
Med Pk Hosp, Antalya, Turkey
Ciceri, F:
Osped San Raffaele Srl, Milan, Italy
Beelen, D:
Univ Hosp, Essen, Germany
Chevallier, P:
CHU Nantes, Nantes, France
Selleslag, D:
Acad Hosp St Jan, Brugge, Belgium
Blaise, D:
Inst Paoli Calmettes, Marseille, France
Foa, R:
Sapienza Univ, Rome, Italy
Corradini, P:
Univ Milan, Milan, Italy
Castagna, L:
Ist Clin Humanitas, Rozzano, Italy
Moreno, C:
Hosp Santa Creu & Sant Pau, Barcelona, Spain
Solano, C:
Univ Valencia, Hosp Clin Univ INCLIVA, Valencia, Spain
Muller, LP:
Martin Luther Univ Halle Wittenberg, Halle, Germany
Tischer, J:
LMU Univ Hosp Munich, Campus Grosshadern, Munich, Germany
Hilgendorf, I:
Univ Klinikum Jena, Klin Innere Med 2, Abt Hamatol & Internist Onkol, Jena, Germany
Hallek, M:
Univ Cologne, Cologne, Germany
Bittenbring, J:
Univ Saarland, Homburg, Germany
Theobald, M:
Univ Med Ctr Mainz, Mainz, Germany
Schetelig, J:
Tech Univ Dresden, Univ Hosp, Dresden, Germany
DKMS Clin Trials Unit, Dresden, Germany
Kroger, N:
Univ Hosp Eppendorf, Hamburg, Germany
Bronze, Green Published
|